Instrument Inactif

Communiqués Medgenics, Inc. NYSE

Actions

US58436Q2030

Recherche biotechnologique et médicale

Cours en clôture NYSE Autres places de cotation
- ^USD	-

29/11/18	Transcript : Aevi Genomic Medicine, Inc. - Special Call
13/03/18	Transcript : Aevi Genomic Medicine, Inc., Q4 2017 Earnings Call, Mar 13, 2018

Communiqués

03/02/20	AEVI GENOMIC MEDICINE, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	AQ
23/12/19	AEVI GENOMIC MEDICINE, INC. : Unregistered Sale of Equity Securities, Regulation FD Disclosure, Other Events (form 8-K)	AQ
11/12/19	AEVI GENOMIC MEDICINE : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K/A)	AQ
10/12/19	AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
05/12/19	AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
22/11/19	AEVI GENOMIC MEDICINE, INC. : Other Events (form 8-K)	AQ
20/11/19	AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement (form 8-K)	AQ
15/10/19	Aevi Genomic Medicine, Inc. : Receives Positive Nasdaq Listing Determination	PR
07/08/19	Aevi Genomic Medicine : Enters into License Agreement with AstraZeneca for Anti-IL-18 Antibody	PR
06/08/19	Aevi Genomic Medicine : to Present at the 2019 Wedbush PacGrow Healthcare Conference	PR
15/07/19	Aevi Genomic Medicine : Enters into Worldwide License Agreement with Astellas to Develop and Commercialize a Novel Second Generation mTORC1/2 Inhibitor	PR
02/01/19	Aevi Genomic Medicine : Announces Top-Line Results from Placebo-Controlled ASCEND Trial (Parts A & B) of AEVI-001 in Children with ADHD	PR
26/11/18	Aevi Genomic Medicine : to Host KOL Breakfast to Discuss Diagnosis and Treatment Paradigms in ADHD	PR
01/11/18	Aevi Genomic Medicine : Reports Third Quarter 2018 Financial Results and Provides Business Update	PR
15/10/18	Aevi Genomic Medicine : Announces Completion of Enrollment for Part B of the ASCEND Trial	PR
29/08/18	Aevi Genomic Medicine : to Present at the H.C. Wainwright 20th Annual Global Investment Conference	PR
21/08/18	Aevi Genomic Medicine : Announces Capital Raise of $4.9M to Accelerate Part B of the ASCEND Trial	PR
14/08/18	Aevi Genomic Medicine : Announces Completion of Enrollment in Part A of Phase 2 ASCEND Trial in ADHD	PR
02/08/18	Aevi Genomic Medicine : Reports Second Quarter 2018 Financial Results and Provides Business Update	PR
19/07/18	Aevi Genomic Medicine, Inc. : Announces Novel Co-crystal Version of AEVI-001	PR
13/06/18	Aevi Genomic Medicine : to Present at the The 2018 JMP Securities Life Sciences Conference	PR
12/06/18	Aevi Genomic Medicine : Provides Update on Sample Size Re-estimation for Phase 2 ASCEND Trial in ADHD	PR
29/05/18	Aevi Genomic Medicine : to Present at the Jefferies 2018 Global Healthcare Conference	PR
15/05/18	Aevi Genomic Medicine : Reports First Quarter 2018 Financial Results and Provides Business Update	PR
30/04/18	Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Aevi Genomic Medicine, Inc. -- GNMX	BU